Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer DOI Creative Commons
Yao Sun,

Michael F. Cronin,

Monique Culturato Padilha Mendonça

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2023, Volume and Issue: 185, P. 106427 - 106427

Published: March 21, 2023

Prostate cancer remains a serious condition threatening the health of men. Due to complicated nature tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), double-stranded non-coding RNA, regulates specific gene expression through interference. Tumour-associated macrophages (TAMs) potential target in immunotherapy. Colony stimulating factor-1/colony factor-1 receptor (CSF-1/CSF-1R) signaling pathway plays crucial role polarization immunosuppressive TAMs, M2 macrophages. Downregulation CSF-1R is known reprogram macrophages, immunostimulatory phenotype, M1 Sialic acid ligand for Siglec-1 (CD169) which overexpressed on with little other phenotypes. Therefore, sialic acid-targeted cyclodextrin-based nanoparticle was developed specifically deliver siRNA The nanoparticles were studied vitro using both human mouse prostate cell lines. Results show that targeted achieved delivery via acid-CD169 axis. significantly downregulated (29.64% vs 19.31% non-targeted THP-1-derived 38.94% 18.51% RAW 264.7-derived n = 4, p < 0.01). resulting reprograming enhanced level apoptosis cells Transwell model (49.17% 37.68% PC-3 69.15% 44.73% TRAMP C1 cells, 3, Thus, this drug system provides strategy

Language: Английский

Nanomaterials loaded with Quercetin as an advanced tool for cancer treatment DOI
Carlos Caro, Mehrab Pourmadadi,

Mohammad Mahdi Eshaghi

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2022, Volume and Issue: 78, P. 103938 - 103938

Published: Nov. 3, 2022

Language: Английский

Citations

47
Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody DOI Creative Commons
Hao Wu, Guoli Wei, Lixia Luo

et al.

Biomaterials Research, Journal Year: 2022, Volume and Issue: 26(1)

Published: Sept. 30, 2022

Combination of chemotherapy and immune checkpoint inhibitor therapy has greatly improved the anticancer effect on multiple malignancies. However, efficiency triple-negative breast cancer (TNBC) is limited, since most patients bear "cold" tumors with low tumor immunogenicity. Doxorubicin (DOX), one effective agents, can induce immunogenic cell death (ICD) thus initiating response.In this study, to maximize ICD induced by DOX, chitosan cell-penetrating peptide (R6F3)-modified nanoparticles (PNPs) loaded ginsenoside Rg3 (Rg3) were fabricated using self-assembly technique, followed co-encapsulation DOX based thermo-sensitive hydrogel. Orthotopic model contralateral established observe antitumor efficacy hydrogel combined anti-PD-L1 immunotherapy, besides, biocompatibility was also evaluated histopathological.Rg3-PNPs strengthened DOX. Moreover, co-loading Rg3-PNPs provoked stronger response in originally nonimmunogenic 4T1 than monotherapy. Following combination PD-L1 blocking, substantial achieved due recruitment memory T cells decline adaptive enrichment.The encapsulating highly permeable provided an efficient strategy for remodeling immunosuppressive microenvironment converting into "hot" tumors.

Language: Английский

Citations

47
Nano-enabled colorectal cancer therapy DOI
Qingqing Pan, Fan Xi, Li Xie

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 362, P. 548 - 564

Published: Sept. 9, 2023

Language: Английский

Citations

35
Flavonoids nanostructures promising therapeutic efficiencies in colorectal cancer DOI

Sepideh Hassani,

Hossein Maghsoudi, Fahimeh Fattahi

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 241, P. 124508 - 124508

Published: April 20, 2023

Language: Английский

Citations

31
Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer DOI Creative Commons
Yao Sun,

Michael F. Cronin,

Monique Culturato Padilha Mendonça

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2023, Volume and Issue: 185, P. 106427 - 106427

Published: March 21, 2023

Prostate cancer remains a serious condition threatening the health of men. Due to complicated nature tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), double-stranded non-coding RNA, regulates specific gene expression through interference. Tumour-associated macrophages (TAMs) potential target in immunotherapy. Colony stimulating factor-1/colony factor-1 receptor (CSF-1/CSF-1R) signaling pathway plays crucial role polarization immunosuppressive TAMs, M2 macrophages. Downregulation CSF-1R is known reprogram macrophages, immunostimulatory phenotype, M1 Sialic acid ligand for Siglec-1 (CD169) which overexpressed on with little other phenotypes. Therefore, sialic acid-targeted cyclodextrin-based nanoparticle was developed specifically deliver siRNA The nanoparticles were studied vitro using both human mouse prostate cell lines. Results show that targeted achieved delivery via acid-CD169 axis. significantly downregulated (29.64% vs 19.31% non-targeted THP-1-derived 38.94% 18.51% RAW 264.7-derived n = 4, p < 0.01). resulting reprograming enhanced level apoptosis cells Transwell model (49.17% 37.68% PC-3 69.15% 44.73% TRAMP C1 cells, 3, Thus, this drug system provides strategy

Language: Английский

Citations

28